We read with great interest the recent chronic hepatitis B (CHB) (AASLD) practice guideline written eminently by 2 of the most experienced hepatologists in CHB.1 Hepatitis B e antigen (HBeAg)-negative CHB is characterized by increased levels of alanine aminotransferase (ALT)/ aspartate aminotransferase (AST), serum hepatitis B virus (HBV)-DNA , 2,000 IU/mL, and moderate/severe necroinflammation, whereas the inactive hepatitis B surface antigen (HBsAg) carrier state is defined as persistently normal ALT/AST on ≥3-4 determinations made every 3 months (then every 6-12 months) and HBV-DNA , 2,000 IU/mL.1. According to our unpublished, recent, prospective cohort of 150 HBeAg-negative chronic HBV patients with a close biochemical and virological follow-up, a substantial proportion (22% of cases or 28% of 228 serum samples tested) of 85 patients with persistently normal ALT/AST levels have HBV-DNA , 2,000 IU/mL (15% at 2,000-5,000 IU/mL and 7% at 5,000-20,000 IU/mL). Such patients are excluded from ...
Buy our Recombinant Hepatitis B Virus E Antigen protein. Ab91273 is an active full length protein produced in Escherichia coli and has been validated in WB…
BioAssay record AID 378283 submitted by ChEMBL: Inhibition of Hepatitis B virus E antigen activity in human MS-G2 cells at 10 ug/mL.
TY - JOUR. T1 - Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients. T2 - A long term cohort study. AU - Brunetto, Maurizia Rossana. AU - Oliveri, Filippo. AU - Coco, Barbara. AU - Leandro, Gioacchino. AU - Colombatto, Piero. AU - Gorin, Juliana Monti. AU - Bonino, Ferruccio. PY - 2002. Y1 - 2002. N2 - Background/Aims: We studied the influence of biochemical and virologic patterns and interferon on the outcome of anti-HBe positive chronic hepatitis B in 164 (103 treated) consecutive patients, followed-up prospectively for a mean of 6 years (21 months-12 years). Methods: Histology, biochemical and virologic profiles were characterized by monthly monitoring during the first 12 months of follow-up. Thereafter patients underwent blood and clinical controls every 4 and 6 months, respectively. Cirrhosis at follow-up histology or end stage complications of cirrhosis served as end points for the analysis of factors influencing disease progression in ...
TY - JOUR. T1 - Retroviral-mediated transfer and expression of hepatitis B e antigen in human primary skin fibroblasts and Esptein-Barr virus-transformed B lymphocytes. AU - Raney, A. K.. AU - Milich, D. R.. AU - Hughes, J. L.. AU - Sorge, J.. AU - Chisari, F. V.. AU - Mondelli, M. U.. AU - McLachlan, A.. PY - 1989. Y1 - 1989. N2 - Previously, an amphotropic retroviral expression system coding for the neomycin resistance gene was developed and used to synthesize hepatitis B e antigen (HBeAg) and hepatitis B core/e antigen (HBc/eAg) in transfected mouse NIH 3T3 fibroblasts (A. McLachlan et al., 1987, J. Virol. 61, 683-692). In the present study, these transfected cell lines were infected with a helper amphotropic murine leukemia virus resulting in the production of infectious recombinant retrovirus. The recombinant retrovirus was examined for its capacity to transmit resistance to the antibiotic, G418, and to express hepatitis B virus antigens in mouse NIH 3T3 fibroblasts, human primary skin ...
Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.. Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug.. ...
Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.. Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug.. ...
Hepatitis b e antigen definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up now!
Tseng, T.-C., Liu, C.-J., Yang, H.-C., Su, T.-H., Wang, C.-C., Chen, C.-L., Fang-Tzu Kuo, S., Liu, C.-H., Chen, P.-J., Chen, D.-S. and Kao, J.-H. (2012), Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology, 55: 68-76. doi: 10.1002/hep.24615 ...
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of "NTU Repository" with "Academic Hub" to form NTU Scholars.. ...
Background & Aims: A previous 4-week trial of telbivudine in patients with chronic hepatitis B indicated marked antiviral effects with good tolerability, leading to the present 1-year phase 2b trial. Methods: This randomized, double-blind, multicenter trial evaluated the efficacy and safety of telbivudine 400 or 600 mg/day and telbivudine 400 or 600 mg/day plus lamivudine 100 mg/day (Comb400 and Comb600) compared with lamivudine 100 mg/day in hepatitis B e antigen (HBeAg)-positive adults with compensated chronic hepatitis B. Results: A total of 104 patients were randomized 1:1:1:1:1 among the 5 groups. Median reductions in serum hepatitis B virus (HBV) DNA levels at week 52 (log 10 copies/mL) were as follows: lamivudine, 4.66; telbivudine 400 mg, 6.43; telbivudine 600 mg, 6.09; Comb400, 6.40; and Comb600, 6.05. At week 52, telbivudine monotherapy showed a significantly greater mean reduction in HBV DNA levels (6.01 vs 4.57 log 10 copies/mL; P < .05), clearance of polymerase chain ...
Hepatitis B surface antigen, hepatitis B e antigen, hepatitis B virus DNA, alanine aminotransferase, liver histology, quantification
International Journal of Hepatology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the medical, surgical, pathological, biochemical, and physiological aspects of hepatology, as well as the management of disorders affecting the liver, gallbladder, biliary tree, and pancreas.
Mouse monoclonal antibody raised against recombinant hepatitis B virus e antigen. Recombinant protein corresponding to hepatitis B virus e antigen. (MAB0466) - Products - Abnova
Result 184 patients (mean age 53.9 years, 67.9% male) were recruited. The cumulative rate of virologic relapse at 24 and 48 weeks was 74.2% and 91.4%, respectively. The median HBV DNA level at virologic relapse was 11 000 (range 2115 to ,1.98×108) IU/mL. 42 (25.8%) patients had elevated alanine aminotransferase (median level 97 U/L, range 37-1058 U/L) during virologic relapse. Mean rate of off-treatment HBsAg decline was 0.018 (±0.456) log IU/mL/year. No patients cleared HBsAg. There was no correlation between off-treatment serial HBsAg and HBV DNA levels (r=−0.026, p=0.541). HBsAg levels at the time of entecavir commencement, entecavir cessation and the subsequent rate of HBsAg reduction were not associated with virologic relapse (all p,0.05).. ...
Different guidelines exist for the management of hepatitis B virus (HBV)-infected healthcare workers (HCWs). Various HBV DNA levels are used as a cutoff level to determine whether an HBV-infected healthcare worker is allowed to perform exposure-prone procedures (EPPs) or not. OSAP member and Arthur A. Dugoni Pacific School of Dentistry faculty member, Eve Cuny MS, has done extensive research on this topic. The Board of OSAP thanks Ms. Cuny for her generosity in sharing articles, a sample policy and a copy of a presentation she made on this topic at the 2009 OSAP Annual Symposium.. If readers have additional materials they wish to contribute to this toolkit, please click HERE ...
Objective: To assess risk factors for liver-related death, we re-evaluated, after a median follow-up of 25 years, a cohort of 70 Caucasian patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis (CH) at presentation.. Methods: Follow-up studies included clinical and ultrasound examinations, biochemical and virological tests, and cause of death.. Results: Sixty-one (87%) patients underwent spontaneous HBeAg seroconversion. During a median period of 22.8 years after HBeAg seroclearance, 40 (66%) patients became inactive carriers, whereas the remaining 21 (34%) showed alanine aminotransferase elevation: one (1%) had HBeAg reversion, nine (15%) detectable serum HBV DNA but were negative for HBeAg, eight (13%) concurrent virus(es) infection and three (5%) concurrent non-alcoholic fatty liver disease. Liver-related death occurred in 11 (15.7%) patients, caused by hepatocellular carcinoma in five and liver failure in six. The 25-year survival probability was 40% in patients persistently ...
T cell proliferative responses to hepatitis B virus-encoded envelope antigen (S + preS2 + preS1), recombinant core antigen (HBcAg), and natural hepatitis B e antigen (HBeAg) were examined in 22 HBeAg-positive patients with chronic type B hepatitis and 17 healthy hepatitis B surface antigen (HBsAg) carriers. The results showed that HBeAg-positive patients had (a) higher levels of T cell responses to HBcAg/HBeAg than those of healthy HBsAg carriers (P less than 0.001 and P less than 0.01, respectively); (b) a further increase in these T cell responses during acute exacerbations (P less than 0.05 and P less than 0.05, respectively); (c) subsidence in the T cell responses to HBcAg/HBeAg after recovery from acute exacerbations and HBeAg seroconversion, whereas the responses would persist at high levels if the patients did not enter a clinical remission; and (d) low levels of T cell responses to S + preS2 + preS1 either before or after HBeAg seroconversion. The appearance of increasing T cell ...
When a patient with hepatitis B e antigen positive infection undergoes treatment, we like to see the patient lose their e antigen and gain e antibody. That tells us the patient has \
High baseline serum levels of interleukin (IL)-23 can help to identify hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who are likely to respond to pegylated interferon (PegIFN) treatment, a Chinese study indicates. Baseline serum levels of the cytokines … Continue reading →. ...
Hepatitis B virus (HBV), a small and economically packaged double-stranded DNA virus, represents an enormous global health care burden. In spite of an effective vaccine, HBV is endemic in many countries. Chronic hepatitis B (CHB) results in the development of significant clinical outcomes such as liver disease and hepatocellular carcinoma (HCC), which are associated with high mortality rates. HBV is a non-cytopathic virus, with the hosts immune response responsible for the associated liver damage. Indeed, HBV appears to be a master of manipulating and modulating the immune response to achieve persistent and chronic infection. The HBV precore protein or hepatitis B e antigen (HBeAg) is a key viral protein involved in these processes, for instance though the down-regulation of the innate immune response. The development of new therapies that target viral proteins, such as HBeAg, which regulates of the immune system, may offer a new wave of potential therapeutics to circumvent progression to CHB ...
Objective To examine viral evolutionary changes and their relationship to hepatitis B e antigen (HBeAg) seroconversion. Design A matched case-control study of HBeAg seroconverters (n=8) and non-seroconverters (n=7) with adequate stored sera before seroconversion was performed. Nested PCR, cloning and sequencing of hepatitis B virus (HBV) precore/core gene was performed. Sequences were aligned using Clustal X2.0, followed by construction of phylogenetic trees using Pebble 1.0. Viral diversity, evolutionary rates and positive selection were then analysed. Results Baseline HBV quasispecies viral diversity was identical in seroconverters and non-seroconverters 10 years before seroconversion but started to increase approximately 3 years later. Concurrently, precore stop codon (PSC) mutations appeared. Some 2 years later, HBV-DNA declined, together with a dramatic reduction in HBeAg titres. Just before HBeAg seroconversion, seroconverters had HBV-DNA levels 2 log lower (p=0.008), HBeAg titres 310-fold smaller
The long-term goal of chronic hepatitis B (CHB) treatment is improvement of liver disease and prevention of cirrhosis. The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis. The primary objective was to evaluate the proportion of patients with absence/minimal inflammation (Knodell necroinflammatory score a parts per thousand currency sign3) on liver biopsy at Year 5.. Fifty-seven patients aged 16-70 years with a clinical history of CHB and active viral replication (38 hepatitis B e antigen [HBeAg] positive and 19 HBeAg negative) were followed for 6 years: 33 received telbivudine 600 mg/day continuously for 5 years; 24 received lamivudine 100 mg/day for 2 years and then telbivudine for 3 years. Liver biopsies were taken pre-treatment and after 5 years of treatment.. At baseline, mean (standard deviation) serum hepatitis B virus (HBV) DNA load was 8.5 (1.7) log(10) copies/mL, Knodell necroinflammatory score was 7.6 (2.9), and Ishak ...
Factors that Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa Erik. H.C.J. Buster, Bettina E. Hansen, George K.K. Lau , Teerha Piratvisuth, Stefan Zeuzem, Ewout W. Steyerberg and Harry L.A. Janssen Gastroenterology 2009; 137(6): 2002-2009. ...
Our previous OSST study shows that switching to pegylated interferon (Peg-IFN)-α2a results in higher rates of response hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss at the end of treatment, compared with nucleot(s)ide analogues (NAs) monotherapy in long term NA-treated chronic hepatitis B (CHB) patients. In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study ...
Book Hepatitis B e (Envelope) Antibody In New Delhi online from Prednalytics Laboratory. View test prices, normal range, sample results and user reviews about labs only on 1mg
In May 1995 a dentist practising in central Scotland was discovered to be hepatitis B e antigen seropositive and therefore highly infectious. The dentist ceased clinical practice immediately and an incident team was convened.. The 6,753 patients treated by the dentist during his professional career were identified and cross-matched with the records of notifications and laboratory diagnoses of hepatitis B since 1988. No patients were shown to have developed clinical hepatitis B subsequent to treatment by the dentist.. The incident group then debated whether there should be any further action. One view expressed was that since routine data sources had identified no clinical cases of hepatitis B amongst the dentists patients, the probability of undetected transmission was very low. A "look back" exercise notifying the dentists former patients would therefore cause them unnecessary anxiety with little health benefit. The contrasting view was that patients had the right to know that they had been ...
During Malaria Treatment I was tested for HbSAg and which was found reactive and hence we gone for HBeAg and ANTI HBcAg-IgM Which was found negative .. So what is its meaning and should I go for Vaccin...
This study is to evaluate the safety, tolerability, and efficacy of nivolumab treatment with or without GS-4774 in adults with HBeAg-negative chronic hepatitis
I would want to know what the HBV DNA result is -- if it is suppressed that would be great news. If so, I would check the HBe Antibody as well. If that is positive, then that would be additional...
A close friend was recently diagnosed as having Hep B. After a 2nd test the results have come back HBeag cutoff marker 1.00, score 0.157 - non reactive Anti HBeag cutoff marker 1.00, score 0.344 -...
A precore mutant is a variety of hepatitis B virus that does not produce hepatitis B virus e antigen (HBeAg). These mutants are important because infections caused by these viruses are difficult to treat, and can cause infections of prolonged duration and with a higher risk of liver cirrhosis. The mutations are changes in DNA bases from guanine to adenine at base position 1896 (G1896A), and from cytosine to thymine at position 1858 (C1858T) in the precore region of the viral genome. The HBV has four genes: S, P, C, and X. The S gene codes for the "major" envelope protein (HBsAg). The largest gene is P. It codes for DNA polymerase. The C gene codes for HBeAg and HBcAg. The C gene has a precore and a core region. If translation is initiated at the precore region, the protein product is HBeAg. If translation begins with the core region, HBcAg is the protein product. HBeAg is a marker of HBV replication and infectivity. The precore region is not necessary for viral replication. Precore mutants can ...
Definition of hepatitis B e antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
This exploratory study investigated nivolumab with or without GS-4774 in patients with HBeAg negative chronic hepatitis B infection
Background & aims Virological breakthrough (VBT) could be a manifestation of chronic hepatitis B (CHB) in patients treated with long-term nucleot(s)ide analogues. We aimed to determine the association of on-treatment serum hepatitis B virus (HBV) DNA with VBT in HBeAg-positive CHB patients receiving entecavir (ETV) treatment. Methods A retrospective cohort study, including 162 consecutive patients (95 men and 67 women; mean age, 43.1±13.4 years) with HBeAg-positive CHB treated with ETV for at least 48 weeks between August 2008 and May 2015, was conducted. Univariate and multivariate cox regression analysis were used to identify associations with VBT and clinical factors, including HBV DNA and HBeAg serum status. Results Among the 162 ETV-treated HBeAg-positive CHB patients, eighteen patients (11.1%) experienced VBT (VBT group), whereas the other 144 patients were without VBT (non-VBT group). The cumulative rate of HBV DNA | 100 IU/mL in the VBT group and the non-VBT group at week 48 were 44.44% and
TY - JOUR. T1 - Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. AU - Byung, Chul Yoo. AU - Ju, Hyun Kim. AU - Chung, Young Hwa. AU - Kwan, Sik Lee. AU - Seung, Woon Paik. AU - Soo, Hyung Ryu. AU - Byung, Hoon Han. AU - Han, Joon Yeol. AU - Kwan, Soo Byun. AU - Cho, Mong. AU - Lee, Heon Ju. AU - Kim, Tae Hun. AU - Cho, Se Hyun. AU - Park, Joong Won. AU - Um, Soon Ho. AU - Seong, Gyu Hwang. AU - Young, Soo Kim. AU - Lee, Youn Jae. AU - Chae, Yoon Chon. AU - Kim, Byung Ik. AU - Lee, Young Suk. AU - Yang, Jin Mo. AU - Haak, Cheoul Kim. AU - Jae, Seok Hwang. AU - Choi, Sung Kyu. AU - Kweon, Young Oh. AU - Jeong, Sook Hyang. AU - Lee, Myung Seok. AU - Choi, Jong Young. AU - Kim, Dae Ghon. AU - Yun, Soo Kim. AU - Heon, Young Lee. AU - Yoo, Kwon. AU - Yoo, Hee Won. AU - Lee, Hyo Suk. PY - 2007/5. Y1 - 2007/5. N2 - Clevudine is a pyrimidine analogue with potent and sustained antiviral activity against HBV. The present study ...
2011) Viruses 3, 83-101.. Hepatitis B virus (HBV) genomes are small, semi-double-stranded DNA circular genomes that contain alternating overlapping reading frames and replicate through an RNA intermediary phase. This complex biology has presented a challenge to estimating an evolutionary rate for HBV, leading to difficulties resolving the evolutionary and epidemiological history of the virus. Here, we re-examine rates of HBV evolution using a novel data set of 112 within-host, transmission history (pedigree) and among-host genomes isolated over 20 years from the indigenous peoples of the South Pacific, combined with 248 previously published HBV genomes. We employ Bayesian phylogenetic approaches to examine several potential causes and consequences of evolutionary rate variation in HBV. Our results reveal rate variation both between genotypes and across the genome, as well as strikingly slower rates when genomes are sampled in the Hepatitis B e antigen positive state, compared to the e antigen ...
It is estimated that there are 350 million world wide carriers of the hepatitis B virus, mostly coming from Asia (Lai et al., 2005). With immigration of Chinese into Western countries, hepatitis B is now becoming established in countries where it was previously uncommon. Chronic hepatitis B infection is a prevalent disease especially in the Toronto and Vancouver areas where most Asians live. Fortunately, over the past decade effective anti-viral treatments have become available. Chronic hepatitis B is mostly an asymptomatic disease, therefore, serological and imaging tests should be used to identify, follow and treat those considered high risk ...
BACKGROUND: The kinetics of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue therapy has not been described. METHODS: We recruited 71 patients achieving persistent viro-logic suppression (Serum HBV DNA < 2,000 IU/mL) during lamivudine therapy for at least 10 years (10 patients for 15 years). Serum HBsAg (Elecsys HBsAg II) and HBV DNA levels (Cobas Taqman) were determined at baseline, year 5 and year 10. HBV genotype was determined by a line probe assay. RESULTS: The median age at lamivudine commencement was 38.6 (range 13.1 to 66.7) years. 57 patients (78.1%) were male and 43 (58.9%) were hepatitis B e antigen (HBeAg)-positive, with all 43 patients achieving HBeAg seroconversion after a median period of 2.82 (range 0.13 to 10.85) months. There was no significant difference in the median annual HBsAg decline rate from baseline to year 5 and from year 5 to 10 (0.350 and 0.359 log IU/mL/year respectively, p = 0.749). There was no difference in median annual ...
PubMedID: 26100697 | Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response. | Antimicrobial agents and chemotherapy | 9/1/2015
In patients with chronic hepatitis B infection, treatment with pegylated interferon has effected a fast and significant decline in hepatitis B virus RNA.
To assess the role of hepatitis B e antigen HBeAg and its interaction with hepatitis B surface antigen HBsAg on the development of hepatocellular carcinoma HCC, this case-control study included 361 age-and sex-matched pairs of patients with histologically proven HCC and healthy control subjects. HBsAg, HBeAg and antibody to HBeAg anti-HBe were...
The SR-domain protein kinase (SRPK) 1 and 2 are two important kinases, which can bind to the hepatitis B virus (HBV) core protein and may be responsible for the phosphorylation of the core protein. The HBV precore protein contains core protein sequence plus an additional 29 amino acids in the N-terminus. The HBV e antigen is formed after processing of the precore to the p22e protein. Here, the role of SRPK1 and SRPK2 in the processing of the precore was determined. SRPK1 and SRPK2 can affect the precore processing in a kinase activity dependent manner; however, they have no significant effect on HBeAg secretion. Using confocal microscopy, I show that precore protein and SRPK2 colocalized, suggesting their physical interaction. Thus, these findings indicate that SRPK1 and SRPK2 can bind and phosphorylate the precore in the cytoplasm and affect the processing of the precore without affecting the HBeAg secretion ...
In approximately 9 years after initiating NA administration, 44 % (17/39) of HBeAg-negative patients and 15 % (8/55) of HBeAg-positive patients were under control without NA. In other words, more than half of HBeAg-negative and most of HBeAg-positive patients still need NA therapy, suggesting difficulty in stopping NA therapy.. In this study we adopted the APASL stopping recommendation [12]. Most of the HBeAg-negative patients (95 %) satisfied this stopping criteria, whereas only one forth of the HBeAg-positive patients (27 %) did. These results are in agreement with a study [15] reporting that seroconversion from HBeAg-positive to HBeAb-positive occurred only in 38 % of HBeAg-positive patients through 4 year-treatment of ETV. Multivariate analysis revealed that patients with lower serum HBV-DNA levels were more likely to meet the stopping criteria in concordance with the previous study [15]. Thus, patients with higher serum HBV-DNA will have difficulty to cease NA treatment once it ...
Looking for online definition of CD49e antigen in the Medical Dictionary? CD49e antigen explanation free. What is CD49e antigen? Meaning of CD49e antigen medical term. What does CD49e antigen mean?
Aims: The aim was to test the efficacy of a pre-S2-containing vaccine (Genhevac-B) in chronic hepatitis B (CHB). Twenty-five naive patients (22 male, three female; median age 35; range: 6-69 years) with CHB were recruited. The inclusion criteria were: hepatitis B e antigen (HBeAg) positive or HBV-DNA detectable with liquid hybridization; alanine aminotransferase (ALT) is at least 1.5-fold the upper normal limit and histological evidence of chronic hepatitis. ...
To date no network meta-analysis (NMA) has accounted for baseline variations in viral load when assessing the relative efficacy of interventions for chronic hepatitis B (CHB). We undertook baseline-adjusted and unadjusted analyses using the same data to explore the impact of baseline viral load (BVL) on CHB treatment response. We searched Embase, Medline, Medline in Process and the Cochrane CENTRAL databases for randomised clinical trials (RCTs) of monotherapy interventions at licensed doses for use in CHB. Search strategies comprised CHB disease and drug terms (a combination of controlled vocabulary and free text terms) and also a bespoke RCT filter. The NMA was undertaken in WinBUGs using fixed and random effects methods, using data obtained from a systematic review. Individual patient data (IPD) from an entecavir clinical trial were used to quantify the impact of different baseline characteristics (in particular undetectable viral load (UVL) at 1 year) on relative treatment effect. Study level mean
Background. Cost and clinically significant adverse effects are the major limiting factors of interferon (IFN) use in therapy for chronic hepatitis B virus (HBV) infection. A clinical trial was conducted in China to study the efficiency and clinical relevance of low-dose regimen of IFN treatment for chronic HBV infection and to reveal factors predicting sustained combined response.. Methods. During a randomized, open-label control study, hepatitis B e antigen (HBeAg)-positive patients with chronic HBV infection (n = 230) were assigned to receive pegylated IFN-α-2b (1.0 µg/kg) (n = 115) or IFN-α-2b (3 MIU; n = 115) for a 24-week period. Sustained combined response was assessed 24 weeks after the completion of treatment.. Results. The greater rate of HBeAg loss in the pegylated IFN-group (23%) was the only statistically significant difference between the 2 treatment arms observed at the end of follow-up. The results of the multivariate statistical analysis revealed that HBV genotype B and ...
After patients completed 96 weeks of treatment and emtricitabine was stopped, patients were followed off treatment for 6 months. Treatment-free follow-up data showed continued virologic response for 19 of 69 patients (28% with HBV DNA levels ≦4700copies/mL), serologic response for 20 of 50 patients (40% seroconversion to anti-HBe), and normal ALT for 38 of 66 patients (58%). Similar relapse rates were observed for both HBeAg positive and HBeAg negative patients for both HBV DNA and ALT, i.e. HBV DNA >LOD and/or ALT abnormal at follow-up week 24 for patients with HBV DNA < LOD and/or ALT normal at week 96. Of the patients who had seroconverted to anti-HBe by week 96 (n=22), four patients reverted to HBeAg positive and one patient lost anti-HBe but remained HBeAg negative at the end of the treatment-free follow-up; the other 17 patients (77%) had stable seroconversion. Of the 78 patients with at least 1 day of follow-up, 15 patients (19%) experienced exacerbation of hepatitis. Generally, ...
Background: In chronic hepatitis B (CHB), the presence of hepatic steatosis (HS) seems to be associated with known host and viral factors which may influence the long-term prognosis of chronic hepatitis B (CHB), probably leading to cirrhosis and hepatocellular carcinoma (HCC). Different from chronic hepatitis C (CHC), factors associated with HS in CHB are not clearly explored. Materials and Methods: 160 CHB patients were divided into two groups depending on the results of liver biopsy. Group I consisted of 71 patients with confirmed steatosis. Group II comprised 89 patients without steatosis. The groups were compared in terms of basal characteristics, body mass index (BMI), liver enzymes (ALT, AST, ALP), serum fasting blood sugar (FBS) and lipids, hepatitis B e antigen (HBeAg), viral load, and histological findings. Results: In terms of host factors, male gender, older age, BMI, high serum FBS and lipid levels were associated with HS. On the other hand, ALT levels, the HAI scores of ...